FDA CRL - Spectrum Pharmaceuticals, Inc.

The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) to Spectrum Pharmaceuticals, Inc. concerning its Biologics License Application (BLA 761148) for SPI-2012. The agency concluded that the application, submitted under section 351(a) of the Public Health Service Act, cannot be approved in its current form due to several unaddressed issues. Key deficiencies include unresolved product quality issues identified during recent inspections of two manufacturing facilities, requiring satisfactory resolution. Additionally, the FDA requires revisions to the proposed prescribing information, carton, and container labeling, emphasizing adherence to regulatory guidance and submission in structured product labeling (SPL) format. The previously acceptable proprietary name, Rolontis, must be resubmitted. A comprehensive safety update is also mandated, necessitating detailed changes in the safety profile, presentation of new and combined safety data with comparative adverse event frequencies, and narrative summaries for serious adverse events or patient discontinuations. Spectrum Pharmaceuticals must fully address all deficiencies and resubmit the application within one year or request an extension.